A 1975 anti-parasitic medicine could prove a game-changer in the fight against cancer.
According to scientists, an anti-parasitic medicine discovered in 1975 could be a “game-changer” in the fight against cancer.
Ivermectin has been used to treat some of the world’s most chronic tropical diseases, including onchocerciasis, helminthiases, and scabies, since its discovery at the Kitasato Institute in Tokyo. Scientists lauded the bacterium endemic to Japanese soil as a wonder medication, but it was continually let down by weak solubility, or its ability to be transformed into a liquid.
Despite the fact that it has cancer-fighting properties, it has been difficult to inject it into patients, making effective research into it impossible for decades.
Mountain Valley MD, a Canadian pharmaceutical business, claims to have discovered a means to dissolve the medicine into a compound called Ivectosol.
They claim that this opens up the prospect of utilizing the medicine in combination with other checkpoint inhibitors to more efficiently target cancer cells.
Checkpoint inhibitors are a type of medicine that aids the immune system in detecting and eliminating malignant cells.
However, due to malignant cells’ particular ability to disguise themselves as healthy cells, they’ve had limited effectiveness to date.
In combination with traditional checkpoint inhibitors, ivermectin could help increase those inhibitors’ ability to detect cancer cells by limiting their ability to hide from the body’s immune system.
Early trials have shown that Ivermectin improves the performance of cancer-fighting checkpoint inhibitors from 5% to over 40%.
When injected directly into a tumor, Ivermectin, according to Mountain Valley MD, can initiate the killing of malignant cells.
The demise of these cells triggers a robust immunological response against the cancer by alerting the body’s immune system to recognize them as a threat.
Mountain Valley believes that its new medicine, Ivectosol, might be a “true game-changer” in cancer therapies, despite the preliminary results.
“Imagine what you could do if you had the world’s only human injectable form that could be injected directly into a tumor or given intravenously. These modes of administration, we believe, will be applicable to a wide range of aggressive cancers.” Mountain Valley MD’s Director of Life Sciences, Mike Farber.
They believe it has the potential to be particularly successful against some of the most invasive and aggressive cancers.
Only 20% of triple-negative breast cancer tumors are recognized by today’s best checkpoint inhibitors, for example.
The company has already given the go-ahead. “Brinkwire News in Condensed Form.”